The STEP trial (Gut, July 2011, Jeppesen et al.) randomized short-bowel patients to teduglutide - a GLP-2 analog - or placebo and showed a meaningful share of treated patients reduced or ended parenteral nutrition and fluid support, the result that underpinned the medicine's approvals (Gattex/Revestive) for intestinal failure.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.